Treatment of systemic sclerosis

Area of Science:

• Rheumatology
• Immunology
• Dermatology

Background:

• Systemic sclerosis treatment remains a significant clinical challenge.
• No definitive disease-modifying interventions were previously established.
• Recent advancements focus on clinical trial outcome measures and response criteria.

Purpose of the Study:

• To review recent intervention studies for systemic sclerosis.
• To evaluate the efficacy and safety of various therapeutic agents.
• To highlight emerging treatment strategies and their potential impact.

Main Methods:

• Review of published intervention studies, including double-blind, placebo-controlled trials and open-label studies.
• Analysis of data on aminobenzoate potassium, antithymocyte globulin, extracorporeal photopheresis, methotrexate, cyclosporine, cyclophosphamide, corticosteroids, iloprost, and octreotide.
• Assessment of treatment effects on skin involvement, pulmonary function, Raynaud's phenomenon, and intestinal pseudoobstruction.

Main Results:

• Aminobenzoate potassium showed no efficacy in a placebo-controlled trial.
• Antithymocyte globulin suggested possible efficacy in small open studies.
• Methotrexate improved skin involvement in most patients; cyclosporine exhibited nephrotoxic side effects.
• Combination therapy with cyclophosphamide and corticosteroids appears promising for pulmonary function.
• Iloprost demonstrated superiority over placebo for scleroderma-related Raynaud's phenomenon.
• Octreotide shows potential benefit for intestinal pseudoobstruction.

Conclusions:

• Current systemic sclerosis treatments offer limited disease modification.
• Combination therapy with cyclophosphamide and corticosteroids shows promise for lung involvement.
• Iloprost is effective for Raynaud's phenomenon.
• Further research is needed to establish definitive treatment protocols and explore novel therapies like octreotide.